Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-11

Clinical Trial Update: Oxytocin to Treat PTSD [Phase 2]

View source ↗

Summary

The VA-sponsored Phase 2 clinical trial evaluating oxytocin for post-traumatic stress disorder has completed, and the results were posted on 2026-03-11.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxytocin (Oxytocin)

Snippet

Sponsor: VA Office of Research and Development | Conditions: PTSD | Phase 2 | Status: COMPLETED | Results posted: 2026-03-11